DDInter282 DDInter131
Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Candida albicans {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Candida albicans {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort